Dupilumab for treating moderate to severe prurigo nodularis (TA955)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Nemolizumab for treating prurigo nodularis in adults ID6451Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC